What changed: Langerhans cell histiocytosis (LCH)
Every dated change on the records linked to Langerhans cell histiocytosis (LCH), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2019 · 2
- 2019GuidelineLangerhans cell histiocytosis (LCH)Guideline Donadieu 2019 (JCO); NCCN histiocytic neoplasms: Refractory risk-organ disease or reactivation
Cladribine plus cytarabine or clofarabine salvage; BRAF inhibitor (vemurafenib or dabrafenib, with trametinib) for BRAF V600E, MEK inhibitor for MAP2K1-mutant disease.
- 2019MilestoneVemurafenibVemurafenib in refractory childhood LCH
Donadieu and colleagues (JCO) report responses in nearly all BRAF V600E children, with reactivation after stopping.
2014 · 1
2013 · 3
- 2013GuidelineLangerhans cell histiocytosis (LCH)Guideline LCH-III (Blood 2013); LCH-IV protocol: Multisystem LCH (first line)
Vinblastine and prednisone for 12 months (LCH-III), with response assessment at 6 weeks; LCH-IV tests further tailoring of duration and intensity.
- 2013Trial resultLCH-IIILCH-III reported
12 vs 6 months of vinblastine-prednisone: 5-year reactivation 37% vs 54% in risk-organ-negative disease; methotrexate added no benefit.
- 2013MilestoneVinblastineLCH-III: 12 months of therapy reduces reactivation
Gadner and colleagues (Blood 2013).